Visão geral da empresa
A clinical-stage biotechnology firm, Kezar Life Sciences, Inc. focuses on the discovery and development of novel small molecule therapeutics designed to address unmet medical needs in immune-mediated diseases within the United States. The company operates within the broader Healthcare sector, specifically positioned in the Biotechnology industry, which typically involves high levels of research and development before achieving commercial product launches. As of the latest data, the firm possesses a market capitalization of $54.18M and maintains a workforce of 9 employees, indicating a highly specialized and lean operational structure. These valuation and staffing metrics suggest that the company is in an early-stage development phase where capital allocation is directed almost exclusively toward advancing clinical programs rather than generating substantial commercial revenue or maintaining a large-scale workforce.
Saúde financeira
The financial statements for Kezar Life Sciences, Inc. reveal a net income of $-56,033,000 and an EBITDA of $-51,373,000 over the trailing twelve months, while revenue data is not available in the current reporting period. The significant gap between the reported net income and EBITDA figures highlights a substantial tax impact or non-operating expenses that erode profitability, as the company operates with a gross margin of 0.0%, an operating margin of 0.0%, and a profit margin of 0.0%. These zero-margin figures are characteristic of clinical-stage entities that incur heavy research costs without yet realizing sales revenue to offset those expenditures. The company holds cash reserves of $71.88M against total debt of $2.33M, resulting in a debt-to-equity ratio of 3.32, which indicates a balance sheet that is heavily leveraged relative to its equity base despite the low absolute debt amount. However, the current ratio stands at 11.52, signaling an exceptionally strong short-term liquidity position where current assets far exceed current liabilities. This liquidity is further evidenced by a free cash flow of $-29,152,250, reflecting cash outflows typical of companies funding their own clinical trials and operational overhead without external financing in the short term. Furthermore, the Return on Equity is recorded at -59.9% and the Return on Assets at -29.5%, metrics that mathematically reflect the dilutive effect of negative earnings on shareholder value and asset efficiency during this pre-revenue stage.
Avaliação de valorização
Valuation metrics for Kezar Life Sciences, Inc. present a challenging picture due to the lack of profitability, with a P/E Ratio (TTM) listed as N/A and a Forward P/E of -2.76, implying that future earnings are projected to be negative or the denominator is negative in the calculation. The Price to Book ratio is 0.77, suggesting that the market values the company at a discount relative to its net asset value, which is common for biotech firms with significant intangible assets not fully captured on the balance sheet. Alternative valuation measures such as the Price to Sales ratio are N/A because the company has not yet generated revenue, while the EV/EBITDA stands at 0.30, indicating a very low enterprise value relative to earnings before interest, taxes, depreciation, and amortization based on current negative earnings. The stock's trading range is bounded by a 52-week high of $7.55 and a 52-week low of $3.53, providing a historical context for price volatility within the biotechnology sector. The beta coefficient is 0.43, which indicates that the stock's price volatility is significantly lower than the broader market, behaving more like a defensive asset despite its high-risk nature as a clinical-stage company.
Growth & Income
The available data indicates that Revenue Growth (YoY) and Earnings Growth (YoY) are both N/A, meaning historical growth rates cannot be calculated for the trailing period. Since the company has not yet achieved commercial revenue, there are no earnings growth rates to compare against revenue expansion, and the distinction between the speed of earnings versus revenue growth is currently theoretical rather than historical. Regarding income distribution, the company does not pay dividends, as evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, which means all available cash and potential future earnings are retained entirely for reinvestment into R&D and clinical operations. This non-dividend status is standard for biotechnology companies in the discovery and development phases, where the priority is capitalizing on asset growth rather than providing income to shareholders. The overall growth and income profile for Kezar Life Sciences, Inc. is defined by a complete absence of current commercial generation and dividend distribution, focusing exclusively on the potential future value creation of its lead product candidate, zetomipzomib (KZR-616).